Causes of Postmenopausal Bleeding
Postmenopausal bleeding (PMB) has a spectrum of causes ranging from benign atrophy to malignancy, but the governing principle is fixed: any postmenopausal bleeding is endometrial cancer until proven otherwise. Although atrophic vaginitis/endometritis is by far the most common cause, roughly 10% of women with PMB have endometrial cancer, so malignancy must be excluded in every case. The evaluation follows a stepwise pathway—transvaginal ultrasound first, then endometrial biopsy, then hysteroscopy with D&C when needed.
Atrophic Vaginitis / Endometritis
The most common cause of postmenopausal bleeding, accounting for 60–80% of cases. Estrogen deficiency leads to thin, friable tissue that bleeds and spots easily, and patients frequently report dyspareunia. Although the urgency is low, you can never assume atrophy without first ruling out cancer. Note that Type II (non-estrogen-related) endometrial cancers—serous and clear cell—arise from atrophic endometrium, so a thin, atrophic-appearing lining does not automatically exclude malignancy.
Endometrial Polyps
Endometrial polyps cause 2–12% of postmenopausal bleeding and appear as focal intracavitary growths. Their urgency is moderate because polyps can harbor cancer. Importantly, because they are focal lesions, a blind office endometrial (Pipelle) biopsy can miss them—persistent bleeding with a non-diagnostic biopsy should prompt hysteroscopy with D&C for direct visualization and complete sampling.
Endometrial Hyperplasia
Endometrial hyperplasia accounts for 5–10% of cases and is a precursor to endometrial cancer, driven by chronic unopposed estrogen. Its urgency is high, particularly when atypia is present. Atypical hyperplasia is essentially preinvasive cancer—many cases labeled atypical hyperplasia are upgraded to frank carcinoma when hysterectomy is performed.
Endometrial Cancer
Endometrial cancer is found in about 10% of women presenting with postmenopausal bleeding and must be excluded in every case—this is the cardinal rule. Risk factors all relate to estrogen exposure: obesity (adipose tissue aromatizes androgens to estrogen), anovulation, unopposed estrogen therapy, and tamoxifen (which acts as an estrogen agonist on the endometrium). Type I cancers (80–90%) are estrogen-related endometrioid adenocarcinomas arising from hyperplasia with a better prognosis; Type II cancers (10–20%) are serous or clear cell, arise from atrophic endometrium, are not estrogen-related, and are more aggressive. Endometrial cancer is staged surgically with total hysterectomy, bilateral salpingo-oophorectomy, and surgical staging. Protective factors include combined oral contraceptives, multiparity, breastfeeding, and smoking (lowers estrogen, though not recommended).
Cervical Pathology
Cervical pathology causes 5–10% of postmenopausal bleeding and characteristically presents as a visible lesion on speculum exam. Urgency is high: any visible cervical lesion should be biopsied directly rather than relying on cytology screening. Recall that cervical cancer is staged clinically (in contrast to the surgical staging of endometrial cancer) and that HPV is the causative agent.
Workup of Postmenopausal Bleeding
Step 1: Transvaginal ultrasound to measure endometrial thickness (double-layer). A thickness ≤4 mm has a negative predictive value >99% for cancer; >4 mm requires tissue sampling. Step 2: Endometrial biopsy—an office procedure with a Pipelle catheter that samples endometrium for histology but can miss focal lesions such as polyps and small cancers. Step 3: Hysteroscopy with dilation and curettage if the biopsy is non-diagnostic or bleeding persists, allowing direct visualization of the cavity and more complete sampling. Important exception: in women on tamoxifen, drug-induced subepithelial cystic changes falsely thicken the endometrial stripe, making TVUS thickness cutoffs unreliable—these patients with abnormal bleeding go directly to endometrial biopsy (or hysteroscopy).
Illustrative Case
A 62-year-old obese woman with type 2 diabetes, hypertension, and 5 years of prior tamoxifen use presents with intermittent postmenopausal spotting. She has stacked estrogen-related risk factors: obesity (peripheral aromatization), diabetes (associated with obesity and hyperinsulinemia), and tamoxifen (endometrial estrogen agonist). Even with a normal Pap history, the presentation demands evaluation for endometrial cancer. Because tamoxifen produces subepithelial cystic changes that falsely thicken the endometrial stripe, the standard TVUS ≤4 mm/>4 mm threshold is unreliable in this patient—she should proceed directly to endometrial biopsy (or hysteroscopy) rather than being triaged by ultrasound thickness.
High-yield
- Any postmenopausal bleeding is endometrial cancer until proven otherwise.
- Atrophic vaginitis/endometritis is the most common cause (60–80%), but ~10% of PMB is endometrial cancer.
- Workup: TVUS first → biopsy if endometrial thickness >4 mm.
- Endometrial thickness ≤4 mm has >99% negative predictive value for cancer.
- In tamoxifen users, TVUS thickness cutoffs are unreliable (drug-induced cystic changes)—go directly to endometrial biopsy.
- Endometrial cancer risk factors relate to estrogen: obesity, anovulation, tamoxifen, unopposed estrogen.
- Type I endometrial cancer = estrogen-driven endometrioid adenocarcinoma from hyperplasia; Type II = serous/clear cell from atrophic endometrium, more aggressive.
- Atypical hyperplasia is essentially preinvasive cancer and is often upgraded to carcinoma at hysterectomy.
- Endometrial cancer is staged surgically; cervical cancer is staged clinically.
- Biopsy any visible cervical lesion directly.
- Protective factors against endometrial cancer: COCs, multiparity, breastfeeding, smoking.
Pitfalls
- Assuming atrophic vaginitis and skipping the malignancy workup—atrophy is common but cancer must be excluded first.
- Believing a thin/atrophic endometrium fully excludes cancer—Type II (serous/clear cell) cancers arise from atrophic endometrium.
- Applying the standard TVUS ≤4 mm/>4 mm threshold to tamoxifen users—drug-induced cystic changes falsely thicken the stripe, so these patients need direct endometrial sampling.
- Relying on a negative blind Pipelle biopsy when bleeding persists—it can miss focal polyps and small cancers; proceed to hysteroscopy with D&C.
- Ordering staging MRI or delaying surgery once endometrial cancer is diagnosed—imaging does not change that surgical staging is needed.
- Confusing staging: cervical cancer is clinical, endometrial cancer is surgical.
- Forgetting tamoxifen acts as an estrogen agonist on the endometrium despite being anti-estrogenic in breast tissue.
- Using cytology instead of biopsy for a visible cervical lesion.
Clinical pearls
- PMB = endometrial cancer until proven otherwise—start with TVUS.
- Endometrial stripe ≤4 mm is reassuring (NPV >99%), >4 mm needs sampling.
- Tamoxifen users with abnormal bleeding bypass the TVUS threshold and go straight to biopsy.
- Persistent bleeding with a non-diagnostic biopsy → hysteroscopy with D&C.
- Obesity fuels endometrial cancer through peripheral aromatization of androgens to estrogen.
- Atypical endometrial hyperplasia should be treated as preinvasive disease.
Frequently asked
What is the most common cause of postmenopausal bleeding?
Atrophic vaginitis/endometritis, accounting for 60–80% of cases. It produces thin, friable tissue, spotting, and dyspareunia, but you cannot assume it without excluding cancer.
What is the most dangerous cause you must exclude in every case?
Endometrial cancer. About 10% of women with postmenopausal bleeding have it, and the cardinal rule is that any postmenopausal bleeding is endometrial cancer until proven otherwise.
What is the first step in evaluating postmenopausal bleeding?
Transvaginal ultrasound to measure endometrial thickness (double-layer). If ≤4 mm, cancer is very unlikely (NPV >99%); if >4 mm, proceed to tissue sampling. An exception is women on tamoxifen, in whom the thickness cutoff is unreliable and you go straight to biopsy.
Why might an office endometrial biopsy miss a cancer?
The Pipelle biopsy samples the endometrium blindly and can miss focal lesions such as polyps and small cancers. If the biopsy is non-diagnostic or bleeding persists, do hysteroscopy with D&C for direct visualization and complete sampling.
How should postmenopausal bleeding be evaluated in a woman on tamoxifen?
Proceed directly to endometrial biopsy (or hysteroscopy) rather than relying on the standard TVUS thickness threshold. Tamoxifen causes benign subepithelial cystic changes that falsely thicken the endometrial stripe, making the ≤4 mm/>4 mm cutoff unreliable in this population.
How does tamoxifen influence endometrial cancer risk?
Tamoxifen acts as an estrogen agonist on the endometrium, increasing the risk of endometrial hyperplasia and cancer—an important consideration even in a woman treated for breast cancer.
What is the significance of atypical endometrial hyperplasia?
Atypical hyperplasia is essentially preinvasive cancer. Many cases are upgraded to frank carcinoma when hysterectomy is performed, so it carries high urgency.
How should a visible cervical lesion causing bleeding be handled?
Biopsy it directly. Cervical pathology accounts for 5–10% of postmenopausal bleeding, and visible lesions warrant biopsy rather than reliance on cytology.
How is endometrial cancer treated and staged once diagnosed?
Endometrial cancer is staged surgically. Standard management is total hysterectomy with bilateral salpingo-oophorectomy and surgical staging; imaging does not replace the need for surgery.
Turn this into reasoning you can use on exam day — practice Causes of Postmenopausal Bleeding on branching cases where your decisions shape the patient.